Navigation Links
Mindray Announces 2008 Fourth Quarter and Full Year Results
Date:3/4/2009

. The Company concluded that the amount of the understatement was not material to the financial statements in any previous periods, nor to the net income for the year ended December 31, 2008 or the trend of earnings. MINDRAY MEDICAL INTERNATIONAL LIMITED RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES Three months ended December 31, Year ended December 31, 2007 2008 2007 2008 US$ US$ US$ US$ (unaudited) (unaudited) (unaudited) (unaudited) (In thousands, except (In thousands, except share and per share data) share and per share data) Net revenues 91,133 167,903 294,295 547,527 Non-GAAP net income 25,155 35,969 88,644 132,671 Non-GAAP net margin 27.6% 21.4% 30.1% 24.2% Amortization of acquired intangible assets, acquired inventory fair value adjustments and IPR&D (641) (2,094) (2,484) (17,373) Deferred tax impact related to acquired intangible assets 96 (651) 373 2,173 Effect of change in tax rate on deferred tax (780) 836 (780) 836 Restructuring charges -- (899) -- (899) Share-based
'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Mindray Medical International Announces Second Quarter 2008 Results
2. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
3. Mindray Medical International Announces First Quarter 2008 Results
4. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
5. Mindray Medical International Announces Third Quarter 2007 Results
6. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
7. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
8. Martek Announces First Quarter 2009 Financial Results
9. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
10. STAAR Surgical Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call
11. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PA (PRWEB) July 30, 2014 Vycom ... family of products, designed to meet Factory Mutual (FM) ... equipment materials such as wet benches, process tools, fume ... worker safety and damage to semiconductor wafers used in ... provides a flame-retardant PVC solution with excellent workability and ...
(Date:7/30/2014)...  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), is ... technologies are used to discover, develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... Vice President and Chief Financial Officer. Tom will ... technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. (OTCBB: ... and development of compounds to safely regress atherosclerotic ... announces that its partner, CardioNova, has accomplished first ... trial with AtheroNova,s lead compound, AHRO-001.  This Phase ... AHRO-001 Phase 1 safety trial completed in February ...
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
Breaking Biology Technology:Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... in Alexandria, VA, the Department of Health and Human ... Accountability (OGAPA) recognized the National Institutes of Health,s Commercialization ... special "team" recognition award for superior efforts to assist ... and "contributing to public health." The award was made ...
... TORONTO, ON Scientists at the University of Toronto, Stanford ... action and function of candidate prescription drugs on human cells, ... a larger scale than ever before. The researchers say ... understanding of a variety of diseases and biologic actions, and ...
... in the Materials Science and Technology division of ... injection, detection and precession of spin accumulation in ... at temperatures up to 225 degrees Celsius. These ... in Si is viable as a basis for ...
Cached Biology Technology:Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium 2University of Toronto chemistry technology promises more effective prescription drug therapies 2NRL scientists achieve high temperature milestone in silicon spintronics 2NRL scientists achieve high temperature milestone in silicon spintronics 3
(Date:7/30/2014)... Oxford University Press (OUP) is pleased to announce its ... Beginning in 2015, OUP and CINP will partner to ... ) as a fully open-access journal. , Alan Frazer, ... that the size and expertise of OUP will further ... become one of the very leading journals within neuropsychopharmacology. ...
(Date:7/30/2014)... received a pledge of $1 million from the Cornelia ... new Neurobehavioral Biometry Center. , The newly ... the Laboratory to develop a greater breadth and depth ... of accelerating the pace of research to improve human ... premier resource for the Laboratory and its external partners, ...
(Date:7/30/2014)... as simple as inserting a medicated, disappearing fabric minutes ... have discovered a potentially faster way to deliver a ... method spins the drug into silk-like fibers that quickly ... of the drug than possible with other topical materials ... women a potentially more effective, discreet way to protect ...
Breaking Biology News(10 mins):OUP to partner with the International College of Neuropsychopharmacology 2Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... frogs like to ,see what they,re getting, when they select ... Michael Reichert from the University of Wisconsin-Milwaukee in the US. ... the importance of vision on male mating behaviors in a ... journal Behavioral Ecology and Sociobiology . Animals display ...
... Shenzhen, China An international research team led by ... genomic sequence of pear by an approach using the ... genome not only provides an invaluable new resource for ... new light on the genome evolution and other genome-wide ...
... 2012 Medbox, Inc. (Ticker: MDBX) ( www.medboxinc.com ), ... have received many inquiries from shareholders purchasing shares of ... volatile trading. These inquiries were responded to and shareholders ... In other news, the company further ...
Cached Biology News:Vision stimulates courtship calls in the grey tree frog 2Pear genome provides new insight into breeding improvement and evolutionary trace analysis 2Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel 2
... SeeDNA co-precipitant, 250 ... pink color ensures easy ... nucleic acid recovery.Chemically inert, ... biology applications.Simple 5-minute protocol. ...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Request Info...
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Biology Products: